In studies where KRAS-mutant NSCLC patients received the MEK inhibitor trametinib plus docetaxel, the ORR was only 12% ~ 17%, with a PFS of approximately 4.0 months.19,50 In other studies in which KRAS-mutant NSCLC patients received the MEK inhibitor selumetinib plus docetaxel, the ORR was 20% ~ 37%, with a PFS of 3.9 ~ 5.3 months and an OS of 8.7 ~ 9.4 months.17,18 Similarly, for KRAS-mutant NSCLC patients receiving anlotinib monotherapy, the ORR was 28%, the median PFS was 4.2 months, and the median OS was 8.0 months. This evidence concerns the gene KRAS and non-small cell lung carcinoma.